MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 408092 | Name: DCN10809
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DCN10809, also known as Paclitaxel succinate NHS ester, is a paclitaxel derivative with a succinic acid linker, in which the carboxy group is activated with an NHS ester. The NHS ester group is highly reactive to amino group or hydroxy group, and can be used to conjugate with other molecules such as peptides, proteins, antibodies or enzymes, or polymers. Paclitaxel-Succinic acid is a useful agent to make Paclitaxel-conjugate for drug delivery, nanodrug research. Note: Paclitaxel-Succinic acid (CAT#620101) is also in stock. This product has no formal name at the moment. For the convenience of communication, a temporal code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming).

Chemical Structure

DCN10809
DCN10809
CAS#245110-80-9

Theoretical Analysis

MedKoo Cat#: 408092

Name: DCN10809

CAS#: 245110-80-9

Chemical Formula: C55H58N2O19

Exact Mass: 1050.3634

Molecular Weight: 1051.06

Elemental Analysis: C, 62.85; H, 5.56; N, 2.67; O, 28.92

Price and Availability

Size Price Availability Quantity
1mg USD 90.00 Ready to ship
5mg USD 150.00 Ready to ship
10mg USD 250.00 Ready to ship
25mg USD 450.00 Ready to ship
50mg USD 750.00 Ready to ship
100mg USD 1,350.00 Ready to ship
200mg USD 2,350.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
33069-62-4 117527-50-1 245110-80-9
Synonym
Paclitaxel succinate NHS ester; DCN10809; DCN-10809; DCN 10809; Paclitaxel-Succinic acid NHS ester
IUPAC/Chemical Name
(1S,2R)-1-benzamido-3-(((2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-diacetoxy-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-9-yl)oxy)-3-oxo-1-phenylpropan-2-yl (2,5-dioxopyrrolidin-1-yl) succinate
InChi Key
DXNRHBJDAAJTTD-CGFZLWGJSA-N
InChi Code
InChI=1S/C55H58N2O19/c1-29-35(72-51(68)45(73-40(63)24-25-41(64)76-57-38(61)22-23-39(57)62)43(32-16-10-7-11-17-32)56-49(66)33-18-12-8-13-19-33)27-55(69)48(74-50(67)34-20-14-9-15-21-34)46-53(6,36(60)26-37-54(46,28-70-37)75-31(3)59)47(65)44(71-30(2)58)42(29)52(55,4)5/h7-21,35-37,43-46,48,60,69H,22-28H2,1-6H3,(H,56,66)/t35-,36-,37+,43-,44+,45+,46-,48-,53+,54-,55+/m0/s1
SMILES Code
CC1(C([C@@H](OC(C)=O)C([C@@](C)([C@]23[H])[C@@H](O)C[C@]4(OC[C@]43OC(C)=O)[H])=O)=C([C@H](C[C@]1([C@H]2OC(C5=CC=CC=C5)=O)O)OC([C@H](OC(CCC(ON6C(CCC6=O)=O)=O)=O)[C@@H](NC(C7=CC=CC=C7)=O)C8=CC=CC=C8)=O)C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related product: CAT#620101 Paclitaxel-Succinic acid; Paclitaxel Succinate; Paclitaxel-hemisuccinic acid; Paclitaxel-SA; https://www.medkoo.com/admins/8185
Biological target:
DCN10809, also known as Paclitaxel succinate NHS ester, is a paclitaxel derivative with a succinic acid linker, in which the carboxy group is activated with an NHS ester.
In vitro activity:
TBD
In vivo activity:
TBD
Solvent mg/mL mM
Solubility
Soluble in DMSO 0.0 0.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 1,051.06 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
1: Banskota S, Saha S, Bhattacharya J, Kirmani N, Yousefpour P, Dzuricky M, Zakharov N, Li X, Spasojevic I, Young K, Chilkoti A. Genetically Encoded Stealth Nanoparticles of a Zwitterionic Polypeptide-Paclitaxel Conjugate Have a Wider Therapeutic Window than Abraxane in Multiple Tumor Models. Nano Lett. 2020 Apr 8;20(4):2396-2409. doi: 10.1021/acs.nanolett.9b05094. Epub 2020 Mar 9. PMID: 32125864. 2: Falah M, Rayan M, Rayan A. A Novel Paclitaxel Conjugate with Higher Efficiency and Lower Toxicity: A New Drug Candidate for Cancer Treatment. Int J Mol Sci. 2019 Oct 8;20(19):4965. doi: 10.3390/ijms20194965. PMID: 31597361; PMCID: PMC6801939. 3: Hu H, Wang B, Lai C, Xu X, Zhen Z, Zhou H, Xu D. iRGD-paclitaxel conjugate nanoparticles for targeted paclitaxel delivery. Drug Dev Res. 2019 Dec;80(8):1080-1088. doi: 10.1002/ddr.21589. Epub 2019 Aug 14. PMID: 31411346. 4: Jin X, Asghar S, Zhang M, Chen Z, Huang L, Ping Q, Xiao Y. N-acetylcysteine modified hyaluronic acid-paclitaxel conjugate for efficient oral chemotherapy through mucosal bioadhesion ability. Colloids Surf B Biointerfaces. 2018 Dec 1;172:655-664. doi: 10.1016/j.colsurfb.2018.09.025. Epub 2018 Sep 15. PMID: 30243219. 5: Zhang D, Zhang J, Li Q, Tian H, Zhang N, Li Z, Luan Y. pH- and Enzyme- Sensitive IR820-Paclitaxel Conjugate Self-Assembled Nanovehicles for Near- Infrared Fluorescence Imaging-Guided Chemo-Photothermal Therapy. ACS Appl Mater Interfaces. 2018 Sep 12;10(36):30092-30102. doi: 10.1021/acsami.8b09098. Epub 2018 Aug 30. PMID: 30118198. 6: Lv Q, Yang J, Zhang R, Yang Z, Yang Z, Wang Y, Xu Y, He Z. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate. Mol Pharm. 2018 May 7;15(5):1842-1852. doi: 10.1021/acs.molpharmaceut.8b00026. Epub 2018 Apr 5. PMID: 29608845. 7: Li F, Lu J, Liu J, Liang C, Wang M, Wang L, Li D, Yao H, Zhang Q, Wen J, Zhang ZK, Li J, Lv Q, He X, Guo B, Guan D, Yu Y, Dang L, Wu X, Li Y, Chen G, Jiang F, Sun S, Zhang BT, Lu A, Zhang G. A water-soluble nucleolin aptamer- paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nat Commun. 2017 Nov 9;8(1):1390. doi: 10.1038/s41467-017-01565-6. PMID: 29123088; PMCID: PMC5680242. 8: Han X, Dong X, Li J, Wang M, Luo L, Li Z, Lu X, He R, Xu R, Gong M. Free paclitaxel-loaded E-selectin binding peptide modified micelle self-assembled from hyaluronic acid-paclitaxel conjugate inhibit breast cancer metastasis in a murine model. Int J Pharm. 2017 Aug 7;528(1-2):33-46. doi: 10.1016/j.ijpharm.2017.05.063. Epub 2017 May 31. PMID: 28576551. 9: Dichwalkar T, Patel S, Bapat S, Pancholi P, Jasani N, Desai B, Yellepeddi VK, Sehdev V. Omega-3 Fatty Acid Grafted PAMAM-Paclitaxel Conjugate Exhibits Enhanced Anticancer Activity in Upper Gastrointestinal Cancer Cells. Macromol Biosci. 2017 Aug;17(8). doi: 10.1002/mabi.201600457. Epub 2017 May 9. PMID: 28485094. 10: Li F, Tang SC. Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB). Genes Dis. 2017 Feb 10;4(1):1-3. doi: 10.1016/j.gendis.2017.01.004. PMID: 30258901; PMCID: PMC6136589. 11: Gao Y, Chen J, Zhang X, Xie H, Wang Y, Guo S. Quantification of Paclitaxel and Polyaspartate Paclitaxel Conjugate in Beagle Plasma: Application to a Pharmacokinetic Study. J Chromatogr Sci. 2017 Mar 1;55(3):222-231. doi: 10.1093/chromsci/bmw174. PMID: 27881491. 12: Wang W, Li M, Zhang Z, Cui C, Zhou J, Yin L, Lv H. Design, synthesis and evaluation of multi-functional tLyP-1-hyaluronic acid-paclitaxel conjugate endowed with broad anticancer scope. Carbohydr Polym. 2017 Jan 20;156:97-107. doi: 10.1016/j.carbpol.2016.08.100. Epub 2016 Aug 31. PMID: 27842858. 13: Zhong T, Yao X, Zhang S, Guo Y, Duan XC, Ren W, Dan Huang, Yin YF, Zhang X. A self-assembling nanomedicine of conjugated linoleic acid-paclitaxel conjugate (CLA-PTX) with higher drug loading and carrier-free characteristic. Sci Rep. 2016 Nov 4;6:36614. doi: 10.1038/srep36614. PMID: 27812039; PMCID: PMC5095675. 14: Yan Q, Yang Y, Chen W, Hu J, Yang D. Construction of polymer-paclitaxel conjugate linked via a disulfide bond. Mater Sci Eng C Mater Biol Appl. 2016 Jan 1;58:580-5. doi: 10.1016/j.msec.2015.09.025. Epub 2015 Sep 10. PMID: 26478347. 15: Yin S, Huai J, Chen X, Yang Y, Zhang X, Gan Y, Wang G, Gu X, Li J. Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid. Acta Biomater. 2015 Oct;26:274-85. doi: 10.1016/j.actbio.2015.08.029. Epub 2015 Aug 20. PMID: 26300335. 16: He X, Lin M, Lu T, Qu Z, Xu F. Molecular analysis of interactions between a PAMAM dendrimer-paclitaxel conjugate and a biomembrane. Phys Chem Chem Phys. 2015 Nov 28;17(44):29507-17. doi: 10.1039/c5cp02242h. Epub 2015 Aug 10. PMID: 26256278. 17: Wu D, Zheng Y, Hu X, Fan Z, Jing X. Anti-tumor activity of folate targeted biodegradable polymer-paclitaxel conjugate micelles on EMT-6 breast cancer model. Mater Sci Eng C Mater Biol Appl. 2015 Aug;53:68-75. doi: 10.1016/j.msec.2015.04.012. Epub 2015 Apr 14. PMID: 26042692. 18: Du AW, Lu H, Stenzel MH. Core-Cross-Linking Accelerates Antitumor Activities of Paclitaxel-Conjugate Micelles to Prostate Multicellular Tumor Spheroids: A Comparison of 2D and 3D Models. Biomacromolecules. 2015 May 11;16(5):1470-9. doi: 10.1021/acs.biomac.5b00282. Epub 2015 Apr 17. PMID: 25857405. 19: Ma P, Zhang X, Ni L, Li J, Zhang F, Wang Z, Lian S, Sun K. Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab. Int J Nanomedicine. 2015 Mar 18;10:2173-90. doi: 10.2147/IJN.S77152. PMID: 25834432; PMCID: PMC4370923. 20: Peng L, Schorzman AN, Ma P, Madden AJ, Zamboni WC, Benhabbour SR, Mumper RJ. 2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model. Int J Nanomedicine. 2014 Jul 30;9:3601-10. doi: 10.2147/IJN.S66040. PMID: 25114529; PMCID: PMC4124067.